Immuron Ltd — Regulatory Filings 2007

Sep 3, 2007

==> picture [68 x 76] intentionally omitted <==

Company Announcement

Anadis makes first international Travelan shipment to South Africa

Tuesday 4 September 2007

Melbourne, Australia. Anadis Limited (ASX:ANX), a research-driven biotechnology company focused on polyclonal antibodies to address human disease, today announces the inaugural international shipment of its Travellers’ Diarrhoea preventative Travelan™ to South Africa.

Travelan[®] is Anadis’ first hyper-immune antibody product scientifically and clinically proven to significantly reduce the risk of Travellers’ Diarrhoea.

The antibodies in Travelan[®] work against E. coli bacteria as they enter the body, preventing them from attaching to the intestinal walls and thereby neutralising their ability to produce toxins and cause Traveller's Diarrhoea and its associated symptoms. In places like India and Mexico, 90% of Travellers’ Diarrhoea is caused by E. coli bacteria.

This first order for Travelan[®] will facilitate the stocking of shelves as well as launch local marketing activities in South Africa by the national distributor Pharmaco.

Anadis Limited CEO Dr Zeil Rosenberg said: “The shipment represents the culmination of a sizeable effort by Anadis, ranging from manufacturing and distribution to international registration and regulatory work.

“The rapid time to market we have achieved compared to the majority of healthcare products is in part due to our natural antibody-based platform and its well-established safety profile. This shipment represents the beginning of a significant penetration into international markets by Anadis’ polyclonal antibody-based healthcare products for the prevention and treatment of disease.”

Many Australian sporting teams have used Travelan[®] , including the Australian Cricket team, Australian A Team and some umpires, Victorian Country under-17 hockey teams, two state cricket teams and the Australian Junior Athletics team.

The Australian Cricket team, in particular, has taken Travelan[®] since April 2006 on its tours to Bangladesh, Malaysia, India and, most recently, the World Cup in the West Indies.

Several other teams, including the Australian junior rowing team, Australian sailing team and cross-country team have also purchased supplies of Travelan[®] for use by athletes and administrators during overseas training in the lead-up to the 2008 Beijing Olympics.

==> picture [49 x 55] intentionally omitted <==

Pharmaco – South Africa

Pharmaco is the South African distributor for several large international clients including Roche, Abbott, ICN/Valeant, Sanofi Pasteur, United Pharmaceuticals and Bioniche. The company has an extensive distribution and marketing network throughout Africa with its head office in South Africa, a subsidiary in the Ivory Coast, and regional offices in Cameroon and Senegal. Pharmaco will be responsible for all marketing activities across the African continent.

Travelan is to be targeted at both domestic travellers and those visiting from abroad. http://www.pharmaco.co.za/

For further information contact:

Dr Zeil Rosenberg (US) - CEO Email: zeil.r@anadis.com.au Tel: +1 201 750 4799

Arie Nudel – Investor Relations Email: arie.n@anadis.com.au Tel: +61 3 9358 6388

Richard Allen – Media

Email: richard@oxygenpr.com.au Tel: +61 3 9915 6341

==> picture [49 x 55] intentionally omitted <==

About Anadis Limited

Anadis Limited (ASX: ANX) is a research-driven biotechnology company focused on antibodybased therapeutic and preventive products. Anadis’ proprietary rapid manufacturing technology has enabled it to develop a product pipeline of polyclonal antibody-based solutions to a range of important infectious and immune-mediated diseases.

The all-natural platform, and its regulatory classification as food rather than as a biological or drug, allows for a significantly shorter time-frame from bench to market compared with typical biotechnology products. The platform also possesses dramatically lower manufacturing costs and higher scalability compared to typical antibody-based solutions.

Anadis is addressing existing market opportunities sized in excess of A$35 billion (US $30 billion).

Via the leveraging of a technology platform that has been carefully developed over a decade, the company expects to become the leading provider of proprietary polyclonal antibody-based solutions worldwide.

Pipeline

Target markets include both products and technologies the company plans to manufacture itself as well as out-license. The pipeline expected to reach the market over the coming few years includes:

• Influenza Oral solution providing immediate-acting prevention and possible treatment of pandemic and seasonal influenza. The Anadis antibody platform allows for rapid modifications of the antibody profile in order to address new, emerging strains (eg avian influenza). Clinical studies are expected to begin in 2008.

• Bio-Defense: Diagnosis, containment and environmental decontamination A health and emergency response worker protection system against anthrax, plague and other bio-warfare agents with expansion potential to more routine bio-hazards including infectious agents, toxins and chemicals. The project received an award from The Australian Defense Department Science and Technology Office.

• Nosocomial infections Oral solutions for the prevention and treatment for top priority hospital and community acquired nosocomial infections. Anadis plans to conduct clinical studies for Clostridium difficile (c. Diff) in 2007-08.

• Enteric disease conditions including:

• Travellers’ Diarrhoea ( enterotoxigenic E. coli ). Anadis’ product, Travelan, is already being sold in Australia and has a global market. Initial shipments are being made to South Africa and Canada.

• Inflammatory bowel disease and irritable bowel syndrome (IBD and IBS). A clinical study for use as an adjunct therapy in patients with Inflammatory Bowel Disease (IBD) started in late 2006 and is being expanded to a multi-centre study.

• Chemotherapy-associated mucositis and Radiotherapy-induced enteritis, diarrhoea and other conditions that involve damage to the GI system. A clinical study begins in 2007.

• BioShielding Proprietary drug-delivery technology to protect orally administered and fragile drugs, antibodies and vaccines from degradation in the digestion system. The technology platform also permits freeze-drying of proteins and vaccines onto dry food, enabling use of dairy-derived antibodies in food. Anadis is in commercialization discussions with pharmaceutical and food manufacturing partners.

• Oncology Several major cancer research groups at major academic medical centers have indicated their interest to co-develop with Anadis the use of polyclonal antibodies in conjunction with their own proprietary oncology treatment approaches. Anadis expects to initiate animal and clinical studies during 2007-08.